Therapy of Hematologic Malignancies Period at high risk of IFI
|
|
- Alannah Johnson
- 5 years ago
- Views:
Transcription
1 Therapy of Hematologic Malignancies Period at high risk of IFI Neutrophils (/mm 3 ) 5 Chemotherapy Conditioning Regimen HSCT Engraftment GVHD + Immunosuppressive Treatment Cutaneous and mucositis : - Direct inoculation (Central catheter) - ingestion or translocation (alimentation, intestinal flora) - Inhalation, Fungal colonisation of GI tractus, mucositis High Incidence of IFI in HSCT recipients : 35 % in case of acute GVHD (grades III-IV) 39 % in case of chronic GVHD chronique (*) * Increase incidence because of RIC, PBSC and Cord blood cell using Jantunen E et al,. Bone Marrow Transplant 1997;19 : 81-8
2 1st Case : The Story of de Mrs H Female, 35 years AML 1 : Diagnosis in october 26 During Induction Therapy - We precribed Posaconazole PO 2 mg TID - She achieved a complete remission (CR1) 2
3 Posaconazole Prophylaxis in Neutropenic Patients Study Overview Posaconazole (n = 34) N = 62 Chemotherapy & prophylaxis Chemotherapy & prophylaxis (if needed) Day 1 postrandomization Fluconazole Itraconazole or (n = 298) Primary end point time period Secondary end point time period Treatment phase (on-treatment period): From randomization up to 7 days after last dose (primary end point time period). 1-day period after randomization (fixed time period): 1 days after randomization (secondary end point time period). Cornely OA et al. N Engl J Med. 27;356: Additional information available in Study Report P1899, p 3,4. SPRI, Kenilworth, NJ, USA; November 25.
4 Posaconazole Prophylaxis in Neutropenic Patients Results Proven/Probable IFI Number of IFIs P <.1 7 2% All IFIs 25 8% Treatment Phase 1* P <.1 2 7% 2 1% Aspergillosis P = % IFI indicates invasive fungal infection. 1. Noxafil [summary of product characteristics]. Brussels, Belgium; SP Europe; Cornely OA et al. N Engl J Med. 27;356: Study report P1899, p 16,18,19. SPRI, Kenilworth, NJ, USA; November 25. All IFIs Posaconazole (n = 34) Standard azoles (n = 298) 33 11% 4 P <.1 1% 26 9% Aspergillosis 1-day Period After Randomization 1-3 *On-treatment period. Fixed-time period.
5 Posaconazole Prophylaxis in Neutropenic Patients Results Time to Invasive Fungal Infection Probability of Invasive Fungal Infection Posaconazole Fluconazole or Itraconazole P =.3* Days After Randomization *Estimated using log-rank statistics. Censoring time is the minimum of the last contact date and day 1. Cornely OA et al. N Engl J Med. 27;356:
6 Posaconazole Prophylaxis in Neutropenic Patients Results Death From Any Cause.3 Posaconazole Probability of Death Fluconazole or Itraconazole P =.4* Days After Randomization *Estimated using log-rank statistics. Censoring time is the minimum of the last contact date and day 1. Cornely OA et al. N Engl J Med. 27;356:
7 Prophylaxis in Neutropenic Patients Serious Treatment-related AEs* Event Event possibly or probably related to treatment Total Bilirubinemia Increased hepatic enzymes Increased alanine aminotransferase Hepatic failure Hepatitis Hepatocellular damage Jaundice Diarrhea Atrial fibrillation Syncope Decreased ejection fraction QT or QTc prolongation Torsades de pointes Diplopia POS (n = 34) 19 (6) 5 (2) 3 (1) 1 (<1) 1 (<1) 1 (<1) 1 (<1) 1 (<1) 1 (<1) 1 (<1) 2 (1) 1 (<1) 1 (<1) 1 (<1) FLU/ITZ (n = 298) 6 (2) 3 (1) 1 (<1) 1 (<1) 1 (<1) Patients, n (%) Standard Azoles FLU (n = 24) 4 (2) 2 (1) 1 (<1) 1 (<1) ITZ (n = 58) * Events are listed for the period from randomization until 3 days after the last dose of the study drug had been administered. Numbers for subentries may not sum to the total numbers because patients could have more than 1 event. QTc denotes the QT interval corrected for heart rate. Prolongation was defined as a period of more than 45 msec for men and more than 47 msec for women. Cornely OA et al. N Engl J Med. 27;356: (3) 1 (2) 1 (2)
8 The Story of de Mrs H In January 27 : She underwent an Allogeneic HSCT from an HLA Identical Unrelated Donor (1/1) after a myeloablative conditioning regimen combining Cyclophosphamide 12 mg/kg and TBI at 12Gy She received a gut decontamination and an antiviral prophylaxis from D-9 to D1
9 Do you prescribe an Antifungal Prophylaxis? 1) No Prophylaxis 2) Yes : - Fluconazole PO Voriconazole PO Ambisome IV Caspofungine IV Posaconazole PO
10 The story of de Mrs H We decided to give : Fluconazole PO 4 mg qd 1
11 Antifungal Prophylaxis Hematologic Malignancies and Allogeneic HSCT 3 Fluconazole Micafungine Itraconazole Caspofungine 26.6 p =,3 25 IFI Incidence (%) Placebo p <,1 * proven proven and probable proven probable, possible FU of 4 weeks 2 p =,4 p = NS p = NS Goodman et al (1)* N = 356 Slavin et al (2)* N = 3 Marr et al (3) N = 34 van Burik et al (4) N = 882 Mattiuzzi et al (5)* N = 2 1. Goodman JL et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326: Slavin MA et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis. 1995;171: Marr KA et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 24;13: van Burik JA et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 24; 39: Mattiuzzi GN et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 26; 5:
12 The story of de Mrs H She well engrafted without any immediate complication and she discharged on D28 with: - Neoral PO (3 mg/kg/day day) - Fluconazole PO 4mg qd - Oracilline, Valaciclovir and Bactrim At Day 36 she developped an acute GVHD of Grade III that we treated with Methylprednisolone (2 mg/kg/day) with maintenance of Neoral 12
13 Antifungal Prophylaxis Do you maintain Fluconazole? Do you switch? For which molecule?
14 The story of de Mrs H We decided to switch to : Posaconazole PO 2mg TID The evolution of the patient was good without any complications and any breakthrough fungal infections.
15 Posaconazole Prophylaxis in Allogeneic HSCT Recipients With GVHD (Double-blind, randomized trial) Posaconazole 2 mg 3x daily or Fluconazole 4 mg oral capsule 1x daily Posaconazole (n = 31) N = 6 First dose Last dose Last dose + 7 days Day 112 Day months (n = 299) Fluconazole Secondary end point time period Primary end point time period Follow-up - Fixed treatment period (fixed-time period) : study period, 112 days - Exposure period (on-treatment period) : time from first study drug dose to 7 days after last dose Principal Objective : Determine efficacy of posaconazole versus fluconazole in preventing proven or probable IFI from randomization to 112 days after first dose Ullmann AJ et al. N Engl J Med. 27;356:
16 Posaconazole Prophylaxis in Allogeneic HSCT Recipients With GVHD Characteristics Acute graft-versus-host disease grade I II III IV Chronic graft-versus-host disease Limited Extensive Posaconazole (n = 31) 3 (1) 135 (45) 52 (17) 12 (4) 2 (1) 96 (32) Fluconazole (n = 299) 1 (<1) 136 (45) 54 (18) 6 (2) 1 (<1) 99 (33) Ullmann AJ et al. N Engl J Med. 27;356:
17 Posaconazole Prophylaxis in Allogeneic HSCT Recipients With GVHD Aspergillus antigen, n (%) Positive (.5 baseline) Negative Missing Immunosuppressive agents, n (%) None Prior antifungal therapy duration Mean ± SD Median (range) Posaconazole (n = 31) 21 (7) 259 (86) 21 (7) 64 (21) 151 (5) 85 (28) 1 (<1) 26.4 ± (-254) Fluconazole (n = 299) 3 (1) 243 (81) 26 (9) 48 (16) 168 (56) 82 (27) 1 (<1) 35.3 ± (-12) Ullmann AJ et al. N Engl J Med. 27;356:
18 Posaconazole Prophylaxis in Allogeneic HSCT Recipients With GVHD Posaconazole (n = 31) Fluconazole (n = 299) Duration of prophylaxis, days Mean ± SD Median (range) 8 ± (1-138) 77 ± (1-13) Ullmann AJ et al. N Engl J Med. 27;356:335-34
19 Number of IFIs Posaconazole Prophylaxis in Allogeneic HSCT Recipients With GVHD P =.7 27 P =.6 9% % 5% 7 7 2% 2% All IFIs Aspergillosis All IFIs P =.4 22 P =.1 8% 17 6% 3 1% Aspergillosis Fixed Treatment Period* Posaconazole n = 31 Fluconazole n = 299 Exposure Period Posaconazole n = 291 Fluconazole n = 288 Ullmann AJ et al. N Engl J Med. 27;356:
20 Posaconazole Prophylaxis in Allogeneic HSCT Recipients With GVHD 2 Probability of Onset of Infection (%) Mean (days) Fluconazole (88) Posaconazole (12) P = * Days From First Dose Ullmann AJ et al. N Engl J Med. 27;356:
21 Posaconazole Prophylaxis in Allogeneic HSCT Recipients With GVHD Cause of death (Investigator assessment), n (%) Total deaths Adverse event Complications related to invasive fungal infection Progression of underlying disease/graft-versushost disease Other Posaconazole n = (25) 39 (13) 4 (1) 31 (1) 2 (1) Fluconazole n = (28) 37 (12) 12 (4) 33 (11) 2 (1) No significant difference in time to death (P =.847) between groups P =.1 by Chi-square test. P =.46 by log-rank test. Ullmann AJ et al. N Engl J Med. 27;356:
22 Prophylaxis in Allogeneic HSCT Recipients With GVHD Body System/Preferred Term Subjects reporting any AE Body as a whole General disorders Anorexia Dizziness Drug level altered Fatigue Headache Weakness Cardiovascular disorders, general Hypertension Central and peripheral nervous system disorders Tremor Disorders of the eye Vision blurred Posaconazole (n = 31) 17 (36) 3 (1) 4 (1) 5 (2) 4 (1) 3 (1) 3 (1) 2 (1) 4 (1) 3 (1) Patients, n (%) Fluconazole (n = 299) 115 (38) 7 (2) 5 (2) 2 (1) 6 (2) 8 (3) 5 (2) 5 (2) 6 (2) 5 (2) Supplementary Appendix to: Ullmann AJ et al. N Engl J Med. 27;356:
23 Prophylaxis in Allogeneic HSCT With GVHD Body System/Preferred Term Gastrointestinal system disorders Abdominal pain Constipation Diarrhea Dyspepsia Nausea Vomiting Liver and biliary system disorders Bilirubinemia GGT increased Hepatic enzymes increased Aspartate aminotransferase increased Alanine aminotransferase increased Posaconazole (n = 31) 4 (1) 1 (<1) 8 (3) 3 (1) 22 (7) 13 (4) 8 (3) 9 (3) 8 (3) 8 (3) 9 (3) Patients, n (%) Fluconazole (n = 299) 7 (2) 5 (2) 12 (4) 6 (2) 28 (9) 15 (5) 5 (2) 7 (2) 7 (2) 3 (1) 4 (1) Supplementary Appendix to: Ullmann AJ et al. N Engl J Med. 27;356:
24 ECIL
25 IDSA
26 1st case: Conclusion In acute myelogenous leukemia patients with neutropenia due to chemotherapy, posaconazole was Significantly better than pooled standard azoles for prophylaxis for Candida and Aspergillus infections Associated with a decrease in all cause mortality at day 1 In hematopoietic stem cell transplant recipients with graft versus host disease, posaconazole was Significantly better than fluconazole for prophylaxis for Candida and Aspergillus infections during the exposure period* Associated with a reduction in invasive fungal infection-related mortality Posaconazole has a safety profile comparable to fluconazole *On-treatment period.
27 2nd Case: The story of de Mrs B The similar story in the beginning but patient maintained fluconazole when she developed GVHD At D 7 : she developed a Fever,, a productive cough, a chest pain and she was hospilalized. The leucocyte count showed 118/mm 3 (16 Neutro) GM Antigenemia was positive at a level of 2.9 The Fibrinogen level was 11.7 g/l 27
28 The story of de Mrs B Chest Xray
29 The story of de Mrs B Scanner 29
30 It is a probable Invasive pulmonary Aspergillosis according to the EORTC criteria What do you do? - Complementary exams? - Specific Treatment? 3
31 The story of de Mrs B We do : A Bronchoalveolar Lavage which showed : - Mycellar filaments at the direct exam and culture showed an Aspergillus Fumigatus - BAL : Ag+ 31
32 Diagnosis of Proven Pulmonary Apergillosis Choice of Antifungal Treatment - Voriconazole IV then PO? - Voriconazole PO? - Caspofungine IV? - Ambisome IV? - Posaconazole PO? - Amphotericine B? - Combinations?
33 The story of de Mrs B - It is a proven IFI (IPA) - We decided to give : Ambisome IV
34 Treatment of First Line International Recommendations ECIL 27 - Voriconazole : AI - Ambisome : BI - Combinations : not recommended IDSA 28 - Voriconazole : AI - Ambisome : AI - Combinations : not recommended
35 The story of de Mrs B Ag Evolution of the Scanner over time on Ambisome IV
36 What do you do in front of IFI worsening? - A new monotherapy : - Caspofungine IV? - Voriconazole IV? - Posaconazole PO? - Other monotherapies? - A combination of antifungal molecules?
37 The story of de Mrs B We decided to give Posaconazole azole PO 4 mg X 2 / day 37
38 The story of de Mrs B 1,5 1,5 Ag Asper Posaconazole
39 Posaconazole Treatment of Refractory Invasive Fungal Infections Patients (%) /17 67/86 Posaconazole (n = 17) External Control (n = 86) 19/17 11/86 9/17 8/86 Pulmonary Extrapulmonary Disseminated. Walsh T et al. Clin Infect Dis. 27;44:2-12
40 Posaconazole Treatment of Refractory Invasive Fungal Infections /17 68/86 Posaconazole (n = 17) External Control (n = 86) 7 Patients (%) /17 18/86 Refractory* Intolerant *Includes subjects who were both refractory and intolerant. Walsh T et al. Clin Infect Dis. 27;44:2-12
41 Posaconazole Treatment of Refractory Invasive Fungal Infections 9 8 Posaconazole (n = 17) External Control (n = 86) Patients (%) /17 46/86 37/17 4/ Proven Probable Study report P2952, p 87. SPRI, Kenilworth, NJ, USA; March 24
42 PosaconazoPosaconazole Treatment of Refractory Invasive Fungal Infections Responders (%) P = /17 22/86 Posaconazole (n = 17) External Control (n = 86) Treatment vs control: OR, 4.6 (95% CI, ). *Primary efficacy analysis (logistic regression). Walsh T et al. Clin Infect Dis. 27;44:2-12
43 Posaconazole Treatment of Refractory Invasive Fungal Infections Survival Distribution Function Posaconazole External Control P =.3 16% absolute difference Survival (all cause mortality, days) Walsh T et al. Clin Infect Dis. 27;44:2-12
44 Posaconazole Treatment of Refractory Invasive Fungal Infections Clinical evidence demonstrates posaconazole is an effective option for invasive aspergillosis refractory to amphotericin B or itraconazole or in patients intolerant of these agents Response, n/total (%) Overall response All Aspergillus spp A fumigatus A flavus A terreus A niger Posaconazole 45/17 (42) 34/76 (45) 12/29 (41) 1/19 (53) 4/14 (29) 3/5 (6) External Control 22/86 (26)* 19/74 (26) 12/34 (35) 3/16 (19) 2/13 (15) 2/7 (29) Posaconazole therapy conferred a survival benefit *P =.6. Mycologically confirmed Aspergillus species including other less known or unknown species Walsh T et al. Clin Infect Dis. 27;44:2-12
45 Posaconazole for Zygomycosis Posaconazole resulted in a 6% success rate in patients with zygomycosis Additional 21% of patients had stable disease Successful outcomes were observed in patients regardless of Infection site Predisposing condition Enrollment reason Primary pathogen Posaconazole may offer an alternative oral treatment to amphotericin B for zygomycosis van Burik J-A et al. Clin Infect Dis. 26;42:e61-e65.
Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationProphylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy?
TIMM-4 18-21 October 2009 Athens, Greece Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy? www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology
More informationHow Can We Prevent Invasive Fungal Disease?
How Can We Prevent Invasive Fungal Disease? Chris Kibbler Professor of Medical Microbiology University College London And Royal Free Hospital, London, UK Invasive Aspergillosis 2 - Acquisition Preventive
More informationWhat have we learned about systemic antifungals currently available on the market?
2nd ECMM/CEMM Workshop Milano, September 25, 2010 What have we learned about systemic antifungals currently available on the market? Prof. Dr. Georg Maschmeyer Dept. of Hematology, Oncology & Palliative
More informationItraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston
REVIEW Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston Division of Hematology-Oncology, Department of Medicine, UCLA Medical Center, Los
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More informationMicafungin, a new Echinocandin: Pediatric Development
Micafungin, a new Echinocandin: Pediatric Development Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University
More informationLondon New Drugs Group APC/DTC Briefing
London New Drugs Group APC/DTC Briefing Posaconazole for invasive fungal infections Contents Background 2 Dosing Information 3 Clinical evidence for treatment of infections 3 Clinical evidence for prophyactic
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs.
More informationPrimary prophylaxis of invasive fungal infection in patients with haematological diseases
Primary prophylaxis of invasive fungal infection in patients with haematological diseases Tunis, May 24 2012 Important questions for antifungal prophylaxis Who are the patients at risk? Which is the risk:
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationAntifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary
Antifungal Agents - Cresemba (isavuconazonium), Noxafil (posaconazole), Vfend (voriconazole) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2,14 Drug FDA Indication(s) Dosing Cresemba
More informationESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole
Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole J.A. Maertens, hematologist, MD, PhD University Hospital Gasthuisberg Leuven, Belgium Current guidelines: first-line
More informationNew Directions in Invasive Fungal Disease: Therapeutic Considerations
New Directions in Invasive Fungal Disease: Therapeutic Considerations Coleman Rotstein, MD, FRCPC, FACP University of Toronto University Health Network Toronto, Ontario Disclosure Statement for Coleman
More informationForm 2046 R3.0: Fungal Infection Pre-HSCT Date
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous
More informationOliver A. Cornely. Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2. Centre for Clinical Research
Management of Confirmed Aspergillosis Oliver A. Cornely 1 Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2 Centre for Clinical Research University of Cologne
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationAntifungal prophylaxis in haematology patients: the role of voriconazole
REVIEW 10.1111/j.1469-0691.2012.03772.x Antifungal prophylaxis in haematology patients: the role of voriconazole Y. Hicheri 1, G. Cook 2 and C. Cordonnier 1 1) Service d Hématologie Clinique, Assistance
More informationChallenges and controversies of Invasive fungal Infections
Challenges and controversies of Invasive fungal Infections Mona Al-Dabbagh, MD, MHSc Assistant Professor of Pediatrics, COM-KSAU-HS Consultant Pediatric Infectious Diseases and Transplant Infectious Diseases
More informationOptimal Management of Invasive Aspergillosis in the Context of New Guidelines in High Risk Haematological Patients
Optimal Management of Invasive Aspergillosis in the Context of New Guidelines in High Risk Haematological Patients Shariq Haider Professor Medicine McMaster University Conflict of Interest Disclosure Slide
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationHOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS?
HOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS? EORTC IFICG START Look for Help? MORTALITYASSOCIATED WITH INVASIVE ASPERGILLOSIS Lin et al. Clin Infect Dis 2001;32:358 100 % 50 n = 178 0 0 60 120
More informationESCMID Online Lecture Library. by author
The antibacterial experience: indications for clinical use of antimicrobial combinations To prevent the emergence of resistant organisms (tuberculosis) To treat polymicrobial infections (abdominal complicated
More informationProphylaxis Limitations: Challenges in the Management of Invasive Aspergillosis
Prophylaxis Limitations: Challenges in the Management of Invasive Aspergillosis Pranatharthi H. Chandrasekar, MD Professor, Department of Medicine Wayne State University School of Medicine Karmanos Cancer
More informationIs pre-emptive therapy a realistic approach?
Is pre-emptive therapy a realistic approach? J Peter Donnelly PhD, FRCPath Department of Haematology Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands Is pre-emptive therapy a realistic
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationTreatment Guidelines for Invasive Aspergillosis
Treatment Guidelines for Invasive Aspergillosis Thomas F. Patterson, MD Professor of Medicine Director, San Antonio Center for Medical Mycology The University of Texas Health Science Center at San Antonio
More informationPrimary Antifungal Prophylaxis in Adult Hematopoietic Stem Cell Transplant Recipients: Current Therapeutic Concepts
Primary Antifungal Prophylaxis in Adult Hematopoietic Stem Cell Transplant Recipients: Current Therapeutic Concepts Dorothy McCoy, Pharm.D., Daryl D. DePestel, Pharm.D., and Peggy L. Carver, Pharm.D. In
More informationVoriconazole October 2015 Risk Management Plan. Voriconazole
Voriconazole October 2015 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Invasive aspergillosis (IA) is the most devastating of Aspergillus related diseases, targeting severely
More informationCombination Antifungal Therapy for Invasive Aspergillosis
MAJOR ARTICLE Combination Antifungal Therapy for Invasive Aspergillosis Kieren A. Marr, 1,2 Michael Boeckh, 1,2 Rachel A. Carter, 1 Hyung Woo Kim, 1 and Lawrence Corey 1,2 1 Fred Hutchinson Cancer Research
More informationUse of Antifungals in the Year 2008
Use of Antifungals in the Year 2008 Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine Diagnosis
More informationTREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS. Part I: EMPIRICAL THERAPY
TREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS Part I: EMPIRICAL THERAPY CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES NIJMEGEN, THE NETHERLANDS n = 328 BACTERIAL INFECTION FUNGAL INFECTION 7% 36%
More informationA CME/CE-CERTIFIED WEBCOURSE. Program Transcript
A CME/CE-CERTIFIED WEBCOURSE Program Transcript Program Steering Committee/Faculty: ELIAS ANAISSIE, MD Medical Director, CTI Clinical Trial and Consulting Services Associate, Metropolitan Infectious Diseases
More informationESCMID Online Lecture Library. by author. CASE PRESENTATION ECCMID clinical grand round May Anat Stern, MD Rambam medical center Haifa, Israel
CASE PRESENTATION ECCMID clinical grand round May 2014 Anat Stern, MD Rambam medical center Haifa, Israel An 18 years old Female, from Ukraine, diagnosed with acute lymphoblastic leukemia (ALL) in 2003.
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationTreatment Guidelines for Invasive Aspergillosis
Treatment Guidelines for Invasive Aspergillosis Thomas F. Patterson, MD Professor of Medicine Director, San Antonio Center for Medical Mycology The University of Texas Health Science Center at San Antonio
More informationManagement Strategies For Invasive Mycoses: An MD Anderson Perspective
Management Strategies For Invasive Mycoses: An MD Anderson Perspective Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA Professor of Medicine Director of Mycology Research Program M. D. Anderson Cancer
More informationHow Can We Tailor Antifungal Therapy?
How Can We Tailor Antifungal Therapy? Russell Lewis Infections Diseases Unit Department of Medical Sciences and Surgery S.Orsola Malpighi Hospital University of Bologna Most Common Infectious Diagnosis
More informationMonitorization, Separation and Quantification of Antifungals used for Invasive Aspergillosis Treatment by High Performance Thin Layer Chromatography
Monitorization, Separation and Quantification of Antifungals used for Invasive Aspergillosis Treatment by High Performance Thin Layer Chromatography M. P. Domingo, M. Vidal, J. Pardo, A. Rezusta, L. Roc,
More informationIsavuconazole. Lepak et al 2013 Antimicrob Agents Chemother 57: Lepak et al 2013 Antimicrob Agents Chemother 57:
Priv.-Doz. Dr. med. Maria J.G.T. Vehreschild Department I of Internal Medicine Clinical Trials Unit II Infectious Diseases Research Group Clinical Microbiome Isavuconazole 09.07.2017 Maria J.G.T. Vehreschild
More informationRezafungin: A Novel Echinocandin. Taylor Sandison, MD MPH Chief Medical Officer ISHAM- Amsterdam July 2, 2018
: A Novel Echinocandin Taylor Sandison, MD MPH Chief Medical Officer ISHAM- Amsterdam July 2, 2018 Disclosures Dr. Sandison is an employee of and stockholder in Cidara Therapeutics. Cidara Pipeline Program
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationAntifungal prophylaxis: Whom, what and when
Antifungal prophylaxis: Whom, what and when Professor Yee-Chun Chen Professor of Medicine National Taiwan University Hospital and College of Medicine; Investigator, National Institute of Infectious Diseases
More informationHAEMATOLOGY ANTIFUNGAL POLICY
HAEMATOLOGY ANTIFUNGAL POLICY PROPHYLAXIS Primary Prophylaxis Patient Group Patients receiving intensive remissioninduction chemotherapy for Acute Leukaemia (excluding patients receiving vinca alkaloids)
More informationDepartment of Pediatric Hematology/Oncology, University Children s Hospital Tübingen, Hoppe-Seyler-Strß 1, Tübingen, Germany 2
Case Reports in Transplantation Volume 2012, Article ID 672923, 4 pages doi:10.1155/2012/672923 Case Report Eradication of Pulmonary Aspergillosis in an Adolescent Patient Undergoing Three Allogeneic Stem
More informationAbstract. Introduction
ORIGINAL ARTICLE MYCOLOGY The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion Y.-Q. Sun, L.-P. Xu,
More informationTop 5 papers in clinical mycology
Top 5 papers in clinical mycology Dirk Vogelaers Department of General Internal Medicine University Hospital Ghent Joint symposium BVIKM/BSIMC and SBMHA/BVMDM Influenza-associated aspergillosis in critically
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationCD101: A Novel Echinocandin
CD101: A Novel Echinocandin Taylor Sandison, MD MPH Chief Medical Officer TIMM Belgrade, Serbia October 8, 2017 1 Disclosures Dr. Sandison is an employee of and stockholder in Cidara Therapeutics 2 Cidara
More informationCurrent options of antifungal therapy in invasive candidiasis
Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationFungal infections. Ematologia. Corrado Girmenia. Ematologia, Azienda Policlinico Umberto I Sapienza University of Rome, Italy
Fungal infections Corrado Girmenia Ematologia, Azienda Policlinico Umberto I Sapienza University of Rome, Italy Ematologia Epidemiology Diagnostic approach Prevention strategies Monitoring of IFDs in
More informationNo Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany
Is Combined Antifungal Therapy More Efficient than Single Agent Therapy? No Evidence As Yet www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam,
More informationAbstract. Introduction. Editor: M. Paul
ORIGINAL ARTICLE MYCOLOGY Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationCLINICAL RESEARCH. Drew J. Winston, Kathy Bartoni, Mary C. Territo, Gary J. Schiller
CLINICAL RESEARCH Efficacy, Safety, and Breakthrough Infections Associated with Standard Long-Term Posaconazole Antifungal Prophylaxis in Allogeneic Stem Cell Transplantation Recipients Drew J. Winston,
More informationADVANCES AND CHALLENGES IN HEMATOLOGY. Invasive fungal disease management in febrile neutropenia
16 th Annual Meeting of Saudi Society of Hematology 7 th Pan Arab Hematology Association Congress ADVANCES AND CHALLENGES IN HEMATOLOGY Invasive fungal disease management in febrile neutropenia J.A. Maertens,
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationPrimary antifungal prophylaxis in leukaemia patients 5
EJC SUPPLEMENTS 5 (2007) 43 48 available at www.sciencedirect.com journal homepage: www.ejconline.com Primary antifungal prophylaxis in leukaemia patients 5 Johan A. Maertens a, *, Pascale Frère b, Cornelia
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More information3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)
3 Results 3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) Five infusions of monoclonal IL-2 receptor antibody (anti-cd25) were planned according to protocol between day 0 and day
More informationSCIENTIFIC DISCUSSION
London, 14 July 2004 Product name: Cancidas Procedure No. EMEA/H/C/379/II/17 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68
More informationLe infezioni fungine nel trapianto di cellule staminali emopoietiche. Claudio Viscoli Professor of Infectious Disease University of Genova, Italy
Le infezioni fungine nel trapianto di cellule staminali emopoietiche Claudio Viscoli Professor of Infectious Disease University of Genova, Italy Potential conflicts of interest Received grants as speaker/moderator
More informationAntifungal Therapy in Leukemia Patients
Antifungal Therapy in Leukemia Patients UPDATE ECIL 4, 6 September 2011 Raoul Herbrecht, Ursula Flückiger, Bertrand Gachot, Patricia Ribaud, Anne Thiebaut, Catherine Cordonnier UPDATE ECIL 4, 2011 UPDATE
More informationInvasive Pulmonary Aspergillosis in
Infection & Sepsis Symposium Porto, April 1-3, 2009 Invasive Pulmonary Aspergillosis in Non-Immunocompromised Patients Stijn BLOT, PhD General Internal Medicine & Infectious Diseases Ghent University Hospital,
More informationEMA Pediatric Web Synopsis Protocol A November 2011 Final PFIZER INC.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationTreatment and Prophylaxis
Treatment and Prophylaxis Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University Children s Hospital
More informationFungal Infection Pre-Infusion Data
Fungal Infection Pre-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: Event date: / / CIBMTR Form 2046 revision 5 (page 1 of 5). Last Updated May, 2018. Infection Episode
More informationamphotericin B empiric therapy; preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET
4 17 9 27 17 1 7 amphotericin B 34 empiric therapy; ET preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET Key words: antifungal therapyempiric therapypreemptive
More informationIndre Vengalyte MD¹, Regina Pileckyte MD¹, Laimonas Griskevicius MD PhD 1, 2
ASPERGILLUS GALACTOMANNAN (GM) ANTIGEN IN THE BRONCHOALVEOLAR LAVAGE (BAL) FLUID FOR THE DIAGNOSIS OF INVASIVE PULMONARY ASPERGILLOSIS (IPA) IN HEMATOLOGICAL PATIENTS Indre Vengalyte MD¹, Regina Pileckyte
More informationProphylactic Strategies for Invasive Fungal Diseases in Hematological Stem Cell Transplantation: An Update
DOI 10.6314/JIMT.201802_29(1).05 2018 29 38-45 Prophylactic Strategies for Invasive Fungal Diseases in Hematological Stem Cell Transplantation: An Update Alice Ying-Jung Wu 1, Hsiang-Kuang Tseng 1,2, and
More informationPAGL Inclusion Approved at January 2017 PGC
Guideline for the prophylaxis and treatment of fungal infections in Haematology patients 1. Introduction PAGL Inclusion Approved at January 2017 PGC Haematology, CHUGGS June 2016 This guideline sets out
More informationAntifungal Update. Candida: In Vitro Antifungal Susceptibility Testing
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationBlood and Marrow TRANSPLANTATION
A Publication of the American Society for Transplantation Issues in Hematology, Oncology, and Immunology VOLUME 17 NO 2 2007 IN THIS ISSUE INTRODUCTION 1 MEMBERSHIP APPLICATION 2 ASBMT NEWS 3 CME PROGRAM:
More informationCase Studies in Fungal Infections and Antifungal Therapy
Case Studies in Fungal Infections and Antifungal Therapy Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017 Disclosures No financial disclosures or industry
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationNationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationESCMID Online Lecture Library. by author
How To Best Use Antifungal Agents Cornelia Lass-Flörl Division of Hygiene and Medical Microbiology Innsbruck Medical University ESCMID SUMMER SCHOOL 2012 Epidemiology Diagnosis Roadmap Antifungal drugs
More informationInvasive aspergillosis in pediatric patients
Current Medical Research and Opinion ISSN: 0300-7995 (Print) 1473-4877 (Online) Journal homepage: http://www.tandfonline.com/loi/icmo20 Invasive aspergillosis in pediatric patients William J. Steinbach
More informationSolid organ transplant patients
M.6 Meet-the-expert sessions Solid organ transplant patients Martin Iversen, Denmark José M. Aguado, Spain Copenhagen, Sunday 13 October 2013 Conflict of interest disclosure In the past 5 years, J.M.A.
More informationFungal Infection Post-Infusion Data
Fungal Infection Post-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: Event date: / / Visit: 100 day 6 months 1 year 2 years >2 years. Specify: CIBMTR Form 2146 revision
More informationVoriconazole 200 mg powder for solution for infusion 03 Jun version 3.0 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Voriconazole 200 mg powder for solution for infusion 03 Jun. 2015 version 3.0 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Voriconazole
More informationAntifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco 3/3 blood cultures are positive for an unidentified
More informationEvidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections. Presenter. Disclosures
Evidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections Presenter James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University
More informationTrends in Invasive Fungal Infection (IFI) in Haematology-Oncology Patients. Saturday, April 18, 2015 Charlottetown, P.E.I.
Trends in Invasive Fungal Infection (IFI) in Haematology-Oncology Patients Saturday, April 18, 2015 Charlottetown, P.E.I. Moderator & Speaker: Shariq Haider MD, FRCPC, FACP, CCST(UK), DTMH(UK) Professor
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationInvasive Fungal Infections in Solid Organ Transplant Recipients
Outlines Epidemiology Candidiasis Aspergillosis Invasive Fungal Infections in Solid Organ Transplant Recipients Hsin-Yun Sun, M.D. Division of Infectious Diseases Department of Internal Medicine National
More informationanidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd
Scottish Medicines Consortium Re-Submission anidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd 10 October 2008 The Scottish Medicines Consortium
More informationTIMM 2013 Role of non-culture biomarkers for detection of fungal infections
TIMM 2013 Role of non-culture biomarkers for detection of fungal infections Tom Rogers Clinical Microbiology, Trinity College Dublin Tom Rogers, TCD & St James s Hospital Dublin, Ireland FACTORS INFLUENCING
More informationposaconazole, or prayers
Antifungal therapy: Polyenes, posaconazole, or prayers Michael Kleinberg, MD, PhD Associate Professor of Medicine Head, Infectious Diseases Section Marlene and Stewart Greenebaum Cancer Center University
More informationCombination Antifungal Therapy for Invasive Pulmonary Aspergillosis in a Heart Transplant Recipient
case report Combination Antifungal Therapy for Invasive Pulmonary Aspergillosis in a Heart Transplant Recipient Andres Beiras-Fernandez, 1 * Amir K. Bigdeli, 1 * Thomas Nickel, 2 Sebastian Michel, 1 Peter
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Noxafil) Reference Number: AZ.CP.PHAR.30 Effective Date: 11.16.16 Last Review Date: 09.12.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this
More informationElements for a Public Summary. [Product Name] 40 mg/ml oral suspension. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a Public Summary [Product Name] 40 mg/ml oral suspension VI.2.1 Overview of disease epidemiology Fungi (yeasts) are small organisms that feed by breaking down tissue. In humans, fungi
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationApproach to the Transplant Patient. Amy Musiek, MD AAD Annual Meeting 2018
Approach to the Transplant Patient Amy Musiek, MD AAD Annual Meeting 2018 Disclosures Actelion: speaker, advisory board, investigator Elorac: investigator Kyowa: investigator, advisory board Seattle genetics:
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationFungal Infection in the ICU: Current Controversies
Fungal Infection in the ICU: Current Controversies Andrew F. Shorr, MD, MPH, FCCP, FACP Washington Hospital Center Georgetown University, Washington, DC Disclosures I have served as a consultant to, researcher/investigator
More informationCondition First line Alternative Comments Candidemia Nonneutropenic adults
Recommendations for the treatment of candidiasis. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Condition First line Alternative
More information